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BACKGROUND. Current animal models of prostate cancer (CaP) bone metastasis do not
allowmeasurement of either tumor growth in bone over time or activation of gene promoters in
intraosseous tumors. To develop these methods, we used bioluminescent imaging (BLI) to
determine if expression of receptor activator of NF-kB ligand (RANKL), a pro-osteoclastogenic
factor that promotes CaP bone metastases, is modulated by the bone matrix protein trans-
forming growth factor-b (TGF-b) in vivo.
METHODS. C4-2B human CaP cells were treated with TGF-b in vitro and RANKL mRNA
and protein production were measured by polymerase chain reaction (PCR) and ELISA,
respectively. Then C4-2B cells stably transfected with the RANKL promoter driving luciferase
(lux) were injected intra-tibially into severe combined immundeficient (SCID) mice. Tumors
were subjected to BLI every 2 weeks for 6 weeks and serum prostate specific antigen (PSA)
was measured using ELISA. Vehicle (V), 1,25 dihydroxyvitamin D (VitD), or TGF-b was
administered to mice with established tumors and BLI to measure RANKL promoter activity
was performed. Tumors were then subjected to immunohistochemistry for lux and assayed for
RANKL mRNA levels.
RESULTS. TGF-b induced RANKL protein and mRNA expression and activated the RANKL
promoter activity in a dose-dependent manner in vitro. BLI demonstrated an increase in
intraosseous tumor size over time, which correlated with serum PSA levels. Administration of
TGF-b and VitD to mice with established intraosseous tumors increased lux activity compared
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to V. Intratibial tumor RANKL mRNA expression paralleled the increased promoter activity.
Immunohistochemistry confirmed the presence of lux in the intraosseous tumors.
CONCLUSIONS. These results demonstrate the ability to measure intraosseous tumor
growth over time and gene promoter activation in an established intraosseous tumor in vivo
and also demonstrate that TGF-b induces activates theRANKLpromoter. These results provide
a novel method to explore the biology of CaP bone metastases. Prostate 59: 360–369, 2004.
# 2003 Wiley-Liss, Inc.
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INTRODUCTION
Prostate cancer (CaP) has a great predisposition to
metastasizing to bone where it forms mixture of
osteolytic and osteoblastic lesions (reviewed in Refs.
1,2). The importance of the osteolytic component to the
development of CaP bone metastases has been demon-
strated by both histological examination of clinical
metastases and several in vivo studies [3–6]. CaP-
induced bone resorption is primarily caused by
osteoclasts [7]. Receptor activator of NF-kB ligand
(RANKL), a tumor necrosis factor (TNF) family mem-
ber, plays an essential role for induction of osteoclas-
togenesis through binding and activating RANK on
osteoclast precursors [8]. Osteoprotegerin (OPG) is a
soluble decoy receptor for RANKL and blocks the
binding of RANKL to RANK resulting in inhibition of
osteoclastogenesis [9]. RANKL expression is increased
in CaP cells at bonemetastatic sites of CaP patients [10]
and in some but not all CaP cell lines [5,11]. In addition,
CaP-induced osteoclast activity is mediated through
RANKL and can be inhibited by administration of
OPG [5,6]. Thus, understanding the regulation of
RANKL in CaP cells may help design therapies to
inhibit CaP bone metastases.
RANKL is expressed in a variety of cells including
bone-derived endothelial cells, human umbilical vein
endothelial cells, T lymphocytes, osteoblasts, and bone
marrow stromal cells [12]. However, there are limited
published data regarding the regulation of RANKL
expression. It has been reported that activationofT cells
[13,14], parathyroid hormone [15,16], 1,25-dihydrox-
yvitaminD (VitD) [17], and inflammatory cytokines
[18,19] upregulateRANKLexpression and that vitamin
K downregulates RANKL expression [20]. However,
themechanism of howRANKL expression is regulated
by these factors has not been reported.
The bone extracellular matrix (ECM) is rich in a
variety of growth factors that may influence RANKL
expression. For example, transforming growth factor-b
(TGF-b), which is abundantly stored in bone ECM,
promotes osteoclastogenesis [21]. TGF-b is released
from the bone ECM during cancer-induced bone
resorption [22]. Although TGF-b is release during
bone resorption and may influence CaP progression
in bone, its ability to modulate RANKL expression in
CaP cells is currently unknown.
Evaluating regulation of gene expression at the
gene promoter level is typically done in vitro with
promoter-driven reporter assays or nuclear run on
assays. These assays are typically insensitive and com-
plicated, respectively, and do not necessarily reflect
regulation of the gene in the endogenous environment.
Due to these limitations, improvedmethods to identify
gene promoter activation in vivo would enhance
investigators’ ability to explore gene regulation. In this
study, we tested if TGF-b induces RANKL expression
at the promoter level in established intraosseous
CaP tumors in vivo using a novel method to identify
activation of the promoter in vivo.
MATERIALSANDMETHODS
Reagents
For in vitro experiments, 1,25-dihydroxyvitamin
D3 (VitD3) Sigma-Aldrich, Inc., (St. Louis, MO) was
diluted to 103Mstock solution in ethanol, thendiluted
further in phosphate-buffered saline (PBS) as required.
For in vivo experiments, VitD3 was diluted in pro-
pyleneglycol. TGF-b (R&DSystems,Minneapolis,MN)
was diluted as required into PBS.
Animals
Six-week-old male severe combined immuno-
deficient (SCID) mice (Charles River, Wilmington,
MA) were housed under pathogen-free conditions.
An animal protocol for this study was approved by
the University of Michigan Animal Care and Use
Committee.
Cells
The human prostate C4-2B cells (UroCor, Inc.,
Oklahoma City, OK) are derived from LNCaP cells
through several passages via castrated nude mice and
isolated from the tumor that metastasize to bone [23].
The C4-2B cells were maintained in T medium (80%
Dulbecco’s minimum essential medium (DMEM,
Life Technologies, Inc., Grand Island, NY), 20% F12K
(Irving Scientific, Santa Ana, CA), 3 g/L NaHCO3,
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100U/Lpenicillin G, 100 mg/ml streptomycin, 5 mg/ml
insulin, 13.6 pg/ml triiodothyronine, 5 mg/ml apo-
transferrin, 0.25 mg/ml biotin, 25 mg/ml adenine) that
was supplemented with 10% fetal bovine serum (FBS).
DU-145 and PC-3 CaP cells (American Type Culture
Collection, Manassas, VA) were maintained in RPMI
media supplemented with 10% FBS.
RANKLPromoterCloning
A total of 1 106 recombinants from the human
genomic library (Clontech) were screened by plaque
hybridization using a probe consisting of polymerase
chain reaction (PCR)-amplified exon 1 of the human
RANKL gene as previously published [24]. A 1,974 bp
clone (Genbank AF544022) was isolated. Primer ex-
tension using a poly(T)þ oligo positioned the major
transcriptional initiation site 157 nucleotides upstream
from the initial methionine site, and this was assigned
the þ1 position. The 50-flanking sequence around the
transcription initiation site of the human RANKL gene
contained TATA- and CAAT-boxes at22 and56 bp.
Sac I and Hind III adaptors were ligated onto the
50- and 30-ends, respectively, of the promoter. The
pGL3-Basic vector (Promega, Madison, WI) was
digested with Sac I and Hind III and the modified
promoter fragment was directionally ligated into the
plasmid upstream of the luciferase (lux) coding
sequence. Both strandswere sequenced by the dideoxy
nucleotide terminationmethodwith anABI PRISM 310
automated sequence analyzer (Applied Biosystems)
to confirm the cloning process.
StableTransfection
C4-2B (5 105) cells plated in 60 mm dishes then
were stably co-transfected with RANKL promoter
driving lux plasmid (1 mg) or empty PGL-3-basic vector
as control (1mg)with anexpression vector for neomycin
resistance (pcDNA3.1þ) (0.1 mg) with the use of Super-
Fect reagent (Qiagen, Valencia, CA) according to the
manufacturer’s instructions. Selection for the neomy-
cin resistance was initiated 48 hr after transfection
by adding 600 mg/ml of G418 (Life Technologies, Inc.)
to the culture medium. The selection medium was
changed every 4 days for 5 weeks. Surviving G418-
resistant cells were pooled and tested for lux expres-
sion. Lux expression was stably maintained after ten
passages in the absence of G418.
TumorCell Inoculation
For intratibial injection tumors, single-cell suspen-
sions (3 105 cells) of C4-2B cells in T media were
injected into the right tibia of the male SCID mice
(n¼ 8 per group) as described previously [5]. Briefly,
mice were anesthetized (135 mg ketamine, 15 mg
xylazine/kg body weight), the knee was flexed, and a
26 g, 3/8-inch needle was inserted into the proximal
end of right tibia followed by injection of 20 ml of the
cell suspension.
For subcutaneous tumor development, C4-2B cells
were resuspended in T-media plus 10% FBS and cells
(1 106) were then injected in the flank at 100 ml/site
using a 23 G needle. Subcutaneous tumor growth was
identified by palpation and two perpendicular axes
were measured and the tumor volume was calculated
using the formula: volume¼ lengthwidth2/2, as
previously described [5].
RadiographicAnalysis
Magnified flat radiographs were taken with a
Faxitron (Faxitron X-Ray Corp., Wheeling, IL).
LuciferaseMeasurement
In some instances, as indicated in the figure legends,
in vitro lux production was measured using a lumin-
ometer (Lumat LB9501, Berthold). In other instances,
in vitro and in vivo bioluminescence imaging were
performed on a cryogenically cooled imaging system
(Xenogen Corporation, Alameda, CA) coupled to a data
acquisition computer. The stable transfectant used in
vivo study was first tested in vitro by adding 20-ml
luciferin (40 mg/ml) into the 96-wells plate. Lumines-
cence emitted from the plate was integrated for 1 min
starting immediately after adding luciferin. For the in
vivo study, prior to imaging, animals were anesthe-
tized in an acrylic chamber with 1.5% isofluorane/air
mixture and injected through intraperitoneal with
40 mg/ml of luciferin potassium salt in PBS at a dose
of 150mg/kgbodyweight aspreviouslydescribed [25].
A digital gray scale animal image was acquired
followed by acquisition and overlay of a pseudocolor
image representing the spatial distribution of detected
photon counts emerging from active lux within the
animal. Photon counts emitted from the mouse were
collected for 1 min starting 10 min after injection of
luciferin. Images were processed and photon counts
were quantified using Living Image software (Xenogen
Corporation).
Histopathology and Immunohistochemistry
Histopathology was performed as we have pre-
viously described [5]. Briefly, bone specimens were
fixed in 10% formalin for 24 hr, then decalcified using
12% EDTA for 72 hr. The specimens were then paraffin
embedded, sectioned (5 mM) and stained with hema-
toxylin and eosin (H&E) to assess histology.
Non-stained tissues sections were deparaffinized
and rehydrated then stained for lux with mouse anti-
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lux monoclonal antibody (Sigma) and biotinylated
anti-mouse IgG antibody for detection using perox-
idase staining as recommended by the manufacturer
(mouse ABC Staining Systems; Santa Cruz Biotechnol-
ogy, Santa Cruz, CA).
Western BlotAnalysis
To evaluate the effect of TGF-b on RANKL protein
expression in C4-2B cells (2 106) were plated in T75
flasks and treated with different dose of TGF-b, vehicle
(V), or VitD for 24 hr and the cells washed twice with
PBS and then lysed in RIPA buffer (1 PBS, 1% Non-
idet P-40, 0.5% sodium deoxycholate, 0.1% sodium
dodecyl sulfate (SDS)) with 100 ng/ml PMSF. proteins
(40 mg/lane) from the cell lysates were applied to SDS-
polyacrylamide gel electrophoresis (PAGE) followed
by Western blot analysis with mouse anti-human
RANKL monoclonal antibody (R&D Systems). The
antibody binding was revealed using a horse-
radish peroxidase (HRP)-conjugated anti-mouse IgG
(Amersham Pharmacia Biotech, Piscataway, NJ) and
enhanced chemiluminescence (ECL) blot detection
system (Amersham Pharmacia Biotech).
Real-TimePCR
To isolate total mRNA from tumors within the
mouse tibia, individual tibiae were excised from
the mice and the distal 1 cm of the tibia was isolated
using bone cutters, then ground using a steel bone mill
(BioComp MiniMill, Biomedical Composites, Ltd.,
Ventura, CA) in 1 ml of RNase-free PBS. The ground
substance was vortexed for 1 min, the chips allowed to
settle and the supernatant was aspirated and the pellet
was mixed with 1 ml of Trizol reagent (Life Technol-
ogies, Inc.), vortexed for 30 sec, then homogenized for
three 10 sec intervals and centrifuged at 10,000 rpm for
30 sec. The supernatant is collected and subjected to
total RNA isolation as described by the manufacturer.
To isolate total mRNA from C4-2B cells in vitro, Trizol
Reagent (Life Sciences) was added to the plates as
described by the manufacturer. Total RNA (200 ng)
was subjected to real-time reverse transcription-PCR
(RT-PCR) using a LightCycler SYBR Green I RNA
amplification kit according to the manufacturer’s
instructions (Roche Diagnostics, Indianapolis, IN).
RT-PCR reactions were subjected to 45 cycles of 948C
for 5 sec, 558C for 10 sec, and 728C for 1min. RT-PCR of
glyceraledhyde-3-phosphate dehydrogenase (GAPDH)
transcriptswas used as an internal control to normalize
for loading differences between samples. PCR primers
used for detection of RANKL mRNA consisted of
upstream: 50-GCTTGAAGCTCAGCCTTTTGCTCAT-30
and downstream: 50-GGGGTTGGAGACCTCGATG-
CTGATT-30. PCR primers used for detection of GAPDH
mRNA consisted of upstream: 50-GGAGTCAACG-
GATTTGGT-30 and downstream: 50-GTGATGGGAT-
TTCCATTGAT-30.
Prostate Specif|c Antigen (PSA)Measurement
Blood was collected via tail vein every 2 weeks
during the study and serum was harvested and frozen
at808C until assayed. Total PSA levels in serumwere
determined using the Accucyte Human PSA assay
(Cytimmune Sciences, Inc., College Park, MA). The
sensitivity of this assay is 0.488 ng/ml.
Statistical Analysis
Statistical analysis of the data was performed using
Statview Software (Abacus Concepts, Berkley, CA).
Analysis of variance (ANOVA) was used for initial
analysis followed by Fisher’s protected least signifi-
cance for post-hoc analyses. Differences were consid-
ered to be significantly significant when a P-value
<0.05was found. To compare the relation betweenPSA
and tumor volume, simple linear regression was used.
RESULTS
To determine if TGF-b induces RANKL expression
in C4-2B CaP cells in vitro. C4-2B cells were incubated
with increasing doses of TGF-b then RANKL protein
in the culture media and cellular RANKL mRNA
expressionwasmeasured.Additionally, VitD, a known
inducer of RANKL expression [26], was used as a
positive control. TGF-b induced RANKL protein
expression in dose-responsive fashion with approxi-
mately a fourfold induction at 10 ng/ml of TGF-b
(Fig. 1). Similarly, TGF-b induced RANKL mRNA
expression in dose-responsive fashion with approxi-
mately a sevenfold induction at 10 ng/ml of TGF-b
(Fig. 1). These data indicate that TGF-b can induce
RANKL protein through increasing RANKL mRNA
steady state levels. Increased steady state levels may
be due to either increased transcriptional activation
and/or decreasedmRNAdegradation. To determine if
activation of the RANKL promoter could contribute to
the increased RANKL mRNA expression, we stably
transfectedC4-2B cellswith a lux reporter vectordriven
by the humanRANKLpromoter then treated the stably
transfected cells with TGF-b. RANKL promoter activ-
ity, as indicated by lux levels, was thenmeasured using
luminescent imaging. TGF-b induced RANKL in a
dose-responsive fashion with approximately a 3.7-fold
induction at 10 ng/ml of TGF-b (Fig. 2). VitD also
induced the RANKL promoter as expected. Taken
together, these data demonstrate that TGF-b increases
RANKL expression, in part, through activation of the
RANKL promoter.
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To better recapitulate the RANKL promoter re-
sponse in CaP bone metastases, the response of the
RANKL promoter to TGF-b in vivo in C4-2B CaP
tumors established in bone was evaluated. Accord-
ingly, we injected C4-2B cells stably-transfected with
the RANKL-lux reporter vector into the tibia of mice
and tumor was allowed to grow over 6 weeks. To
identify development of tumors, radiographs of the
tibia were taken every 2 weeks after tumor injection up
to 6 weeks. Radiographic changes were not identified
until 6 weeks after tumor injection (Fig. 3A). They
consisted of mixed osteolytic and osteoblastic changes
as previously reported for C4-2B cells in bone. In
contrast, tumor was identifiable as early as 2 weeks
using bioluminescent imaging (BLI) and increasing
tumor growth in bone was detectable over time using
BLI of living mice (Fig. 3B,C). To ensure that the
increased BLI reflected tumor burden, serum PSA was
measured. The mouse does not make PSA, thus the
serum PSA confirms the C4-2B tumor burden in the
mice. PSA levels increased over time in a similar
fashion to the lux levels (Fig. 3D). The BLI of the tumors
was strongly correlatedwith PSA levels (Fig. 3E). These
data indicate that BLI can be used to non-invasively
measure tumor growth in bone over time in mice.
Once tumors were developed, VitD (as positive
control) and TGF-b were administered to the mice.
Both VitD and TGF-b transiently induced RANKL
promoter activity in the C4-2B cells in bone (Fig. 4A,B).
Fig. 1. Transforming growth factor-b (TGF-b) induces RANKL
protein andmRNAexpression inC4-2B cells.A: C4-2B cellswere
treatedwithvehicle(V),TGF-b,or1,25-dihydroxyvitaminD(VitD3)
for 24 hr at the indicated doses.Total cellular protein from C4-2B
cells was subjected to Western blot analysis for RANKL. Then
themembrane was stripped and reprobed for b-actin.B: RANKL
protein band density was quantified using densitometric analysis.
RANKL bands were normalized to b-actin bands. Results are
reported as mean SD from three independent experiments.
*P< 0.01, **P< 0.001 as compared with vehicle-treated cells. C:
Total RNA was isolated from C4-2B cells treated as indicated.
RANKLmRNAexpressionwasevaluatedbyreal-timePCR.Human
glyceraledhyde-3-phosphate dehydrogenase (GAPDH) mRNA
was used to normalize between samples. Results are reported
as mean SD from three independent experiments, each one
performed with triplicates measurements of PCR products.
*P< 0.01, **P< 0.001ascomparedwithvehicle treatedcells.
Fig. 2. TGF-binducesRANKLtranscriptioninC4-2Bcellsinvitro.
A:C4-2BcellswerestablytransfectedwithhumanRANKLpromo-
ter (1.97 kb) driving luciferase (lux).The stably transfected C4-2B
cloneswerepooledandplatedin96-well-platesandtreatedwithvehi-
cle (V),TGF-b, or1,25-dihydroxyvitaminD(VitD3) for24hr atindi-
cated doses. Luciferin was added to each well and imaging was




tified. Results are reported as the mean SD from duplicates
measurements of pooled clones. *P< 0.01, **P< 0.001 compared
withvehicle. [Color figurecanbeviewedin theonlineissue,whichis
availableatwww.interscience.wiley.com.]
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To determine if the observed pattern of RANKL pro-
moter activity in vivo was due to pharmacokinetics
of VitD or TGF-b, we exposed cells in vitro to these
compounds and measured lux expression. The tran-
sient nature of the RANKL promoter induction was
repeated in vitro (Fig. 4C) indicating this was not a
pharmacokinetic effect. To confirm that VitD and TGF-
b-induced promoter activity was associated with
increased RANKL production in vivo, we measured
RANKL mRNA levels in the bone tumors. Both VitD
and TGF-b induced RANKL mRNA expression
(Fig. 4D). Histology of the tumors was performed and
confirmed the presence of tumor in bone (Fig. 4E).
Furthermore, to confirm that the tumors were making
lux, we performed immunohistochemistry for lux
on the tumor sections. Lux was colocalized within the
tumor cells in bone (Fig. 4E), which confirms that
the C4-2B cells were expressing lux in the tumor site
and that the RANKL promoter was active at this site.
Taken together, these results demonstrate that TGF-b
induces the RANKL promoter in bone and that BLI
imaging can be utilized tomeasure promoter activation
within tumors in vivo.
DISCUSSION
In the current study, we demonstrated both the
ability to quantify activation of a gene promoter in
intraosseous CaP as well as quantify intraosseous CaP
tumor growth over time. In addition to these metho-
dological advances, we identified that TGF-b, a protein
found at high levels in the bone ECM, promotes CaP-
mediated RANKL production through activation, in
part, of the RANKL promoter. Taken together, these
results contribute to both the understanding of how
Fig. 3. Bioluminescentimaging (BLI) canbeused to detect tumorgrowthinboneinvivo over time.C4-2Bprostate cancer (CaP) cellswere
stably transfectedwith a reporter vector of the RANKL promoter driving lux.The transfected C4-2B cells were injected intratibially into
severe combinedimmundeficient (SCID)mice (n¼ 6).Micewere subjected toradiographs andBLI for luxevery 2weekspost-tumor injection
at which time serumwas collected and frozen for prostate specific antigen (PSA) evaluation.A: Radiographs of a mouse tibia injected with
C4-2BCaPcells.Tumor-inducedchangesarenotedbetweenthearrowheads.B:Representativescanof twomicedemonstratingluminescence
in the tibia. Lowermouse is the same as in (A).The scale bar indicates luminescence intensity from high (H) to low (L).C: Quantification of
luminescencefromsixanimals.Photoncountswerecollectedoveraminuteperiod.Resultsarereportedas themean SD.*P< 0.01compared
to the measurement 2 weeks prior.D: Serum PSA levels were determined using ELISA. Results are reported as the mean SD. *P< 0.01
compared to themeasurement2weeksprior.E:Regression analysisbetweenBLI-measured tumor volumeand serumPSA. [Color figure can
beviewedin theonlineissue,whichis availableatwww.interscience.wiley.com.]
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bone crosstalks with CaP, as well as providing new
methodologies to explore bone and CaP crosstalk.
Evaluating promoter activity in vitro is fraught
with inconsistencies. For example, the substrate of the
cell culture plates can influence signaling in the cells,
monolayer cultures do not recapitulate the three
dimensional context of tumor structures, which can
influence cell’s response to compounds or compounds
administered in vitro may be metabolized to another
active (or inactive) compound in vivo. Thus, observa-
tions from in vitro promoter studies may not reflect
the in vivo modulation of the promoter.
Determining gene promoter regulation in vivo is
quite challenging. Recent advances in BLI have allow-
ed for the ability to identify activation of gene pro-
moters in mice genetically modified to express lux
driven by either a constitutive or inducible promoter
[27]. However, evaluation of promoter activation
Fig. 4.
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within cancer cells growing in bone in vivohas not been
described. The current studywasprimarily designed to
develop amethod to identify gene promoter regulation
in vivo in intraosseous tumor cells. Accordingly, in the
current study, we evaluated the known activating
effects of VitD on the RANKL promoter [26] as well as
determining if TGF-b induced RANKL promoter
in vitro, thus setting the groundwork for in vivo
evaluation. Our observation that VitD and TGF-b
induced the RANKL promoter in vivo was supported
by the observation that RANKL mRNA levels in the
tumors paralleled the BLI results. Finally, the demon-
stration that luxwas present in the CaP cells in the bone
confirmed the origin of the lux. Taken together, these
results demonstrate that BLI is a sound method for
measuring promoter activation in bone in vivo.
Monitoring tumor growth in bone metastases
models has been a great challenge due to the inacces-
sibility of the bone. Typically measurement is made
using radiographs.However, radiographs have several
drawbacks, including (1) lack of sensitivity as over 50%
of the bone mineral density has to change prior to it
being detected as a change on radiographs; (2) they
only provide a one dimensional evaluation of the bone
and do not allow quantitative determination of total
tumor volume; and (3) they are an indirect measure of
the tumor, specifically as they only identify the effect of
tumor on bone, not the tumor itself. Thus, results from
the current study indicate that BLI may have advan-
tages over radiographic imaging of bone tumors and
suggest that it is a valuable method for measuring
intraosseous tumor growth. The observation that BLI
measurement of tumor burden paralleled PSA levels
provides a strong level of confidence in the BLI
quantification of tumor burden. However, in addition
to quantifying tumor burden levels, tumor localization
is an advantage that BLI offers over measurement
of PSA. In addition to intraosseous growth, we have
found that BLI can be used to measure subcutaneous
andorthotopicCaPgrowth of stably-transfectedC4-2B,
as well as DU145 and PC-3 CaP cells (data not shown)
similar to its ability to be useful formeasuring response
of brain tumors to chemotherapeutic treatment in
rodents [25]. The subcutaneous tumors demonstrated
a higher basal level of lux compared to the bone tumors
and a similar induction of the promoterwith treatment.
It is unclear if the higher basal lux levels observed in the
subcutaneous tumors was due to microenvironment
effects (i.e., bone vs. subcutaneous sites) or due to the
fact that the subcutaneous-derived signal did not need
to penetrate bone or that there wasmore tumormass in
the subcutaneous tumors.
Several methods of non-invasive imaging of animal
cancer models have been developed (reviewed in
Ref. 28). Micro-positron emission tomography (Micro-
PET) has been used to identify uptake of systemically
and intratumorally administered reporter virus in a
variety of cancer cells (reviewed in Ref. 29) including
CaP cells xenografts in mice [30]. Micro-PET could
identify the tumors; however, significant systemic
transgene leakage occurred resulting in significant
hepatic expression of reporter. This contrasts with the
current study in which lux expression is maintained
at the site of tumor cells. Regardless, the MicroPET
method offers the potential of being able to track gene
therapy in clinical cases. In another study [31], demon-
strated the ability to detect adenoviral-mediated lux
expression was detected in skeletal muscle of mice
using a cooled charged coupled device (CCD) camera.
This method demonstrated great sensitivity for detect-
ing lux for a duration of greater than 150 days.
Similarly, in the current study,we observed lux activity
in tumor cells for an extended period of time (i.e., for
42 days, at which time mice were sacrificed), which
Fig. 4. BLIdetects thatTGF-b activates theRANKLpromoter inC4-2Bcells inboneinvivo.C4-2BCaPcellswere stably transfectedwitha
reporter vector of the RANKL promoter driving lux.The transfected C4-2B cells were injected intratibially into SCIDmice tumors were
allowed to develop over 6 weeks and vehicle (phosphate-buffered saline, PBS),TGF-b (100 ng/mouse), or1,25-dihydroxyvitamin D (VitD3)
(200 ng/mouse) in propylene glycol was then administered intraperitoneally into the mice (n¼ 6/group).The mice were then anesthetized
at the indicated timespre- or post-injection and BLIwas performed.Photon countswere collectedover aminuteperiod.A: Representative
BLIimagesofmice treatedwitheitherTGF-b orVitD3.Thesamemouseis shownover time foreach treatment.The scalebar indicateslumines-
cence intensity fromhigh (H) to low (L).B: Luciferinwas injected10min prior to the desired timepoint for BLImeasurement.Luminescence
emitted from themousewas then integrated for1min starting10 min after injection of luciferin.Results are reported asmean SD (n¼ 6/
group). *P< 0.05, **P< 0.01compared with pre-treatment (pre-) for that compound.C: Stably transfected C4-2B clones were pooled and
plated in12-well-plates and treatedwithTGF-b (10 ng/ml) or1,25-dihydroxyvitamin D (VitD3; 10 nM) for 24 hr.Cells were then collected for
measurementof luxona luminometer.Results arereportedasmean SDof two experiments. *P< 0.05, **P< 0.01comparedwithpre-treat-
ment (pre-) for thatcompound.D: A section of the intratibial tumorsweremechanicallyground and thenhomogenized to collect total RNA
whichwasthensubjectedtoreal-timePCRforRANKLmRNAandGAPDHmRNA.RANKLmRNAlevelswerenormalizedtoGAPDHmRNA
levels.Resultsarereportedasmean SD.*P< 0.01comparedwithvehicle.E: Sectionsof intratibial tumorsweredecalcifiedandprocessedfor
histology.Sectionswerestainedwithhematoxylinandeosin(H&E)or subjectedtoimmunohistochemistry forlux.Thetopsections are100
magnificationandthebottomsections (indicatedby the squares in the top section) are400magnification.Thebarrepresents the cartilage
epiphysis.Boneisrepresentedbypinkosteoid.Tumorcells areseensurroundedbyboneandareindicatedby thearrow.In thelux sections, luxis
representedby thebrowncolor. [Color figurecanbeviewedin theonlineissue,whichis availableatwww.interscience.wiley.com.]
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demonstrates the utility of thismethod for longitudinal
studies.
Cross-talk between tumor and bone occurs has been
postulated to play a major role in the development
of CaP bone metastases [1,2]. The basal levels of
RANKLpromoter activity induced in theC4-2B tumors
implanted into bone may have been due to a variety
of factors that have been shown to induce RANKL
expression including interleukins-1 [32] and -11 [33],
parathyroid hormone [34] and TNF [33]. When CaP
cells grow in bone, they induce bone resorption, which
results in release of many bone ECM factors, including
TGF-b [22]. TGF-b signals through TGFb-I and TGFb-II
receptors which have been identified in normal as
well as in cancerous human and animal prostate cells
[35,36]. However, expression of TGF-b receptors inCaP
is controversial [37], yet several studies have demon-
strated that TGF-b is functional in CaP cells [38–41].
Data from the current manuscript demonstrate that
TGF-b activates the RANKL promoter resulting in
increased RANKL production, which has been re-
ported to allow the CaP cells to induce osteoclastogen-
esis and osteoclast activation that results in bone
resorption [5]. The resorptive component of CaP has
been shown by several studies to be an important
component of the establishment of osteoblastic CaP
bonemetastases [2,6,42]. Thus, results from the current
study suggest that CaP-induce bone resorption, which
releases TGF-b, will further enhance RANKL produc-
tion and more bone resorption in a vicious cycle.
However, due to the overall osteoblastic nature of
CaP, there must be regulation of this osteoclastogenic
activity. One possible regulator of this activity is OPG,
an inhibitor of RANKL, which is produced by CaP
cells [10,43,44] and is elevated in the serumofmenwith
CaP [45].
In conclusion, we described a method to measure
CaP tumor growth in bone over time and a novel
method for determination of promoter activation
within formed CaP tumors in the bone microenviron-
ment in vivo. Using the latter method, we determined
that TGF-b induces RANKL expression through acti-
vation of the RANKL promoter in CaP in bone. This
finding is consistent with the idea the cross-talk
between tumor and bone is important in the develop-
ment of bone metastases [2] and identifies TGF-b as a
potential target to regulate the establishment of CaP
growth in bone. Additionally, the methodology used
to measure promoter activity in vivo should be useful
for determining the influence of microenvironment
(e.g., bone vs. liver metastatic sites) on gene regulation
in cancer cells and can be useful to test the effect on
gene promoter modulation of compounds that are
metabolized to active forms in vivo, which cannot be
tested in vitro. Finally, thismethodology has the poten-
tial to be useful for evaluating therapies designed to
modulate regulation of cancer relevant genes including
monitoring both tumor volume and gene regulation.
REFERENCES
1. Rosol TJ. Pathogenesis of bonemetastases: Role of tumor-related
proteins. J Bone Miner Res 2000;15(5):844–850.
2. Keller ET, Zhang J, Cooper CR, Smith PC, McCauley LK,
Pienta KJ, Taichman RS. Prostate carcinoma skeletal metastases:
Cross-talk between tumor and bone. Cancer Metastasis Rev
2001;20(3–4):333–349.
3. Charhon SA, Chapuy MC, Delvin EE, Valentin-Opran A,
Edouard CM, Meunier PJ. Histomorphometric analysis of
sclerotic bone metastases from prostatic carcinoma special
reference to osteomalacia. Cancer 1983;51(5):918–924.
4. Urwin GH, Percival RC, Harris S, Beneton MN, Williams JL,
Kanis JA. Generalised increase in bone resorption in carcinoma
of the prostate. Br J Urol 1985;57(6):721–723.
5. Zhang J, Dai J, Qi Y, Lin DL, Smith P, Strayhorn C, Mizokami A,
Fu Z, Westman J. Osteoprotegerin inhibits prostate cancer-
induced osteoclastogenesis and prevents prostate tumor growth
in the bone. J Clin Invest 2001;107(10):1235–1244.
6. Yonou H, Kanomata N, Goya M, Kamijo T, Yokose T, Hasebe
T, Nagai K, Hatano T, Ogawa Y, Ochiai A. Osteoprotegerin/
osteoclastogenesis inhibitory factor decreases human prostate
cancer burden in human adult bone implanted into nonobese
diabetic/severe combined immunodeficient mice. Cancer Res
2003;63(9):2096–2102.
7. Clarke NW, McClure J, George NJ. Disodium pamidronate
identifies differential osteoclastic bone resorption in metastatic
prostate cancer. Br J Urol 1992;69(1):64–70.
8. Burgess TL, Qian Y, Kaufman S, Ring BD, Van G, Capparelli C,
Kelley M, Hsu H, Boyle WJ, Dunstan CR, Hu S, Lacey DL. The
ligand for osteoprotegerin (OPGL) directly activates mature
osteoclasts. J Cell Biol 1999;145(3):527–538.
9. Kostenuik PJ, ShalhoubV.Osteoprotegerin: Aphysiological and
pharmacological inhibitor of bone resorption. Curr Pharm Des
2001;7(8):613–635.
10. Brown JM, Corey E, Lee ZD, True LD, Yun TJ, Tondravi M,
Vessella RL. Osteoprotegerin and rank ligand expression in
prostate cancer. Urology 2001;57(4):611–616.
11. Lee Y, Schwarz E, Davies M, Jo M, Gates J, Wu J, Zhang X,
Lieberman JR. Differences in the cytokine profiles associated
with prostate cancer cell induced osteoblastic and osteolytic
lesions in bone. J Orthop Res 2003;21(1):62–72.
12. Kartsogiannis V, Zhou H, Horwood NJ, Thomas RJ, Hards
DK, Quinn JM, Niforas P, Ng KW, Martin TJ, Gillespie MT.
Localization of RANKL (receptor activator of NF kappa B
ligand) mRNA and protein in skeletal and extraskeletal tissues.
Bone 1999;25(5):525–534.
13. WeitzmannMN,Cenci S, Rifas L, Haug J, Dipersio J, Pacifici R. T
cell activation induces human osteoclast formation via receptor
activator of nuclear factor kappaB ligand-dependent and
-independent mechanisms. J Bone Miner Res 2001;16(2):328–
337.
14. Kotake S, Udagawa N, Hakoda M, Mogi M, Yano K, Tsuda E,
Takahashi K, Furuya T, Ishiyama S, Kim KJ, Saito S, Nishikawa
T, Takahashi N, Togari A, Tomatsu T, Suda T, Kamatani N.
Activated humanT cells directly induce osteoclastogenesis from
human monocytes: Possible role of T cells in bone destruction
in rheumatoid arthritis patients. Arthritis Rheum 2001;44(5):
1003–1012.
368 Zhang et al.
15. Locklin RM, Khosla S, Turner RT, Riggs BL. Mediators of the
biphasic responses of bone to intermittent and continuously
administered parathyroid hormone. J Cell Biochem 2003;89(1):
180–190.
16. FuQ, JilkaRL,Manolagas SC,O’BrienCA.Parathyroidhormone
stimulates receptor activator of NFkappa B ligand and inhibits
osteoprotegerin expression via protein kinase A activation
of cAMP-response element-binding protein. J Biol Chem 2002;
277(50):48868–48875.
17. Kitazawa R, Kitazawa S, Maeda S. Promoter structure of mouse
RANKL/TRANCE/OPGL/ODF gene. Biochim Biophys Acta
1999;1445(1):134–141.
18. Collin-Osdoby P, Rothe L, Anderson F, Nelson M, Maloney W,
Osdoby P. Receptor activator of NF-kappa B and osteoprote-
gerin expression by human microvascular endothelial cells,
regulation by inflammatory cytokines, and role in human
osteoclastogenesis. J Biol Chem 2001;276(23):20659–20672.
19. PalmqvistP,PerssonE,ConawayHH,LernerUH. IL-6, leukemia
inhibitory factor, and oncostatin M stimulate bone resorption
and regulate the expression of receptor activator of NF-kappa B
ligand, osteoprotegerin, and receptor activator of NF-kappa B in
mouse calvariae. J Immunol 2002;169(6):3353–3362.
20. Koshihara Y, Hoshi K, Okawara R, Ishibashi H, Yamamoto S.
Vitamin K. Stimulates osteoblastogenesis and inhibits osteoclas-
togenesis in human bone marrow cell culture. J Endocrinol
2003;176(3):339–348.
21. Yan T, Riggs BL, Boyle WJ, Khosla S. Regulation of osteoclas-
togenesis and RANK expression by TGF-beta1. J Cell Biochem
2001;83(2):320–325.
22. Guise TA.Molecular mechanisms of osteolytic bonemetastases.
Cancer 2000;88(Suppl 12):2892–2898.
23. Wu TT, Sikes RA, Cui Q, Thalmann GN, Kao C, Murphy CF,
Yang H, Zhau HE, Balian G, Chung LW. Establishing human
prostate cancer cell xenografts in bone: Induction of osteoblastic
reaction by prostate-specific antigen-producing tumors in
athymic and SCID/bg mice using LNCaP and lineage-derived
metastatic sublines. Int J Cancer 1998;77(6):887–894.
24. Anderson DM, Maraskovsky E, Billingsley WL, Dougall WC,
Tometsko ME, Roux ER, Teepe MC, DuBose RF, Cosman D,
Galibert L. A homologue of the TNF receptor and its ligand
enhance T-cell growth and dendritic-cell function. Nature 1997;
390(6656):175–179.
25. Rehemtulla A, Stegman LD, Cardozo SJ, Gupta S, Hall DE,
Contag CH, Ross BD. Rapid and quantitative assessment of
cancer treatment response using in vivo bioluminescence imag-
ing. Neoplasia 2000;2(6):491–495.
26. KitazawaR,Kitazawa S. VitaminD(3) augments osteoclastogen-
esis via vitamin D-responsive element of mouse RANKL gene
promoter. Biochem Biophys Res Commun 2002;290(2):650–655.
27. ZhangW, Feng JQ,Harris SE, Contag PR, StevensonDK, Contag
CH.Rapid invivo functional analysis of transgenes inmiceusing
whole body imaging of luciferase expression. Transgenic Res
2001;10(5):423–434.
28. Lewis JS, Achilefu S, Garbow JR, Laforest R, Welch MJ. Small
animal imaging: Current technology and perspectives for
oncological imaging. Eur J Cancer 2002;38(16):2173–2188.
29. GambhirSS.Molecular imagingof cancerwithpositronemission
tomography. Nat Rev Cancer 2002;2(9):683–693.
30. Pantuck AJ, Berger F, Zisman A, Nguyen D, Tso CL, Matherly J,
Gambhir SS, Belldegrun AS. CL1-SR39: A noninvasive molecular
imaging model of prostate cancer suicide gene therapy using
positron emission tomography. J Urol 2002;168(3):1193–1198.
31. Wu JC, Sundaresan G, Iyer M, Gambhir SS. Noninvasive optical
imaging of firefly luciferase reporter gene expression in skeletal
muscles of living mice. Mol Ther 2001;4(4):297–306.
32. Weitzmann MN, Cenci S, Rifas L, Brown C, Pacifici R.
Interleukin-7 stimulates osteoclast formation by up-regulating
the T-cell production of soluble osteoclastogenic cytokines.
Blood 2000;96(5):1873–1878.
33. NakashimaT,KobayashiY,Yamasaki S,KawakamiA,EguchiK,
Sasaki H, Sakai H. Protein expression and functional difference
of membrane-bound and soluble receptor activator of NF-
kappaB ligand: Modulation of the expression by osteotropic
factors and cytokines. Biochem Biophys Res Commun 2000;
275(3):768–775.
34. Ma YL, Cain RL, Halladay DL, Yang X, Zeng Q, Miles RR,
Chandrasekhar S, Martin TJ, Onyia JE. Catabolic effects of con-
tinuous human PTH (1–38) in vivo is associated with sustained
stimulation of RANKL and inhibition of osteoprotegerin and
gene-associated bone formation. Endocrinology 2001;142(9):
4047–4054.
35. Wikstrom P, Lindh G, Bergh A, Damber JE. Alterations
of transforming growth factor beta1 (TGF-beta1) and
TGFbeta receptor expressions with progression in Dunning
rat prostatic adenocarcinoma sublines. Urol Res 1999;27(3):
185–193.
36. Wong YC, Xie W, Tsao SW. Structural changes and alteration in
expression of TGF-beta1 and its receptors in prostatic intrae-
pithelial neoplasia (PIN) in the ventral prostate of noble rats.
Prostate 2000;45(4):289–298.
37. Wikstrom P, Damber J, Bergh A. Role of transforming growth
factor-beta1 in prostate cancer. Microsc Res Tech 2001;52(4):
411–419.
38. Steiner MS, Wand GS, Barrack ER. Effects of transforming
growth factor beta 1 on the adenylyl cyclase-cAMP pathway in
prostate cancer. Growth Factors 1994;11(4):283–290.
39. Chipuk JE, Cornelius SC, Pultz NJ, Jorgensen JS, Bonham MJ,
Kim SJ, Danielpour D. The androgen receptor represses trans-
forming growth factor-beta signaling through interaction with
Smad3. J Biol Chem 2002;277(2):1240–1248.
40. Kang HY, Lin HK, Hu YC, Yeh S, Huang KE, Chang C. From
transforming growth factor-beta signaling to androgen action:
Identification of Smad3 as an androgen receptor coregulator
in prostate cancer cells. Proc Natl Acad Sci USA 2001;98(6):
3018–3023.
41. Kim IY, Zelner DJ, Lee C. The conventional transforming
growth factor-beta (TGF-beta) receptor type I is not required
for TGF-beta 1 signaling in a human prostate cancer cell line,
LNCaP. Exp Cell Res 1998;241:151–160.
42. Corey E, Brown LG, Quinn JE, Poot M, Roudier MP, Higano CS,
Vessella RL. Zoledronic acid exhibits inhibitory effects on osteo-
blastic and osteolytic metastases of prostate cancer. Clin Cancer
Res 2003;9(1):295–306.
43. Penno H, Silfversward CJ, Frost A, Brandstrom H, Nilsson O,
Ljunggren O. Osteoprotegerin secretion from prostate cancer is
stimulated by cytokines, in vitro. Biochem Biophys Res Com-
mun 2002;293(1):451–455.
44. Holen I, Croucher PI, Hamdy FC, Eaton CL. Osteoprotegerin
(OPG) is a survival factor for humanprostate cancer cells.Cancer
Res 2002;62(6):1619–1623.
45. Brown JM, Vessella RL, Kostenuik PJ, Dunstan CR, Lange PH,
Corey E. Serum osteoprotegerin levels are increased in patients
with advanced prostate cancer. Clin Cancer Res 2001;7(10):
2977–2983.
Live Imagingof PromoterActivation in IntraosseousTumor 369
